





(A unit of VELS Group, Pallavaram)

Approved by Government of Tamilnadu (Lr. No. TN35013/MCA-2/2003; dt.7.9.2006) Approved by Dental Council of India, New Delhi Approved by Government of India Vide. F. No. V.12017/3/2003-DE, dt. 14.07.2007 & dt.08.11.2011. Ministry of Health & Family Welfare Affiliated to the Tamil Nadu Dr.MGR Medical University

## NAAC ACCREDITED

Off OMR, Near Navalur, Thalambur, Chennai - 600 130 Phone.:7449000052 / 53 / 54 Fax : 044 -2743 5770 E-mail : info@svdentalcollege.com www.svdentalcollege.com

Date: 5-12-2022

This is to certify that the enclosure attached below is the policy followed by

our institution, regarding preventive immunization of the students, teachers

and hospital staff likely to be exposed to communicable diseases during their

clinical work, since inception of the institution.

CERTIFIED







### (A unit of VELS Group, Pallavaram)

Approved by Government of Tamilnadu (Lr. No. TN35013/MCA-2/2003; dt.7.9.2006) Approved by Dental Council of India, New Delhi Approved by Government of India Vide. F. No. V.12017/3/2003-DE, dt. 14.07.2007 & dt.08.11.2011. Ministry of Health & Family Welfare Affiliated to the Tamil Nadu Dr.MGR Medical University

# NAAC ACCREDITED

Off OMR, Near Navalur, Thalambur, Chennai - 600 130 Phone.:7449000052 / 53 / 54 Fax : 044 -2743 5770 E-mail : info@svdentalcollege.com www.svdentalcollege.com

## POLICY REGARDING PREVENTIVE IMMUNISATION OF STUDENTS,

## TEACHERS WHO ARE LIKELY TO BE EXPOSED TO COMMUNICABLE DISEASES

## VACCINATIONS AND IMMUNIZATIONS:

Three- Dose Hepatitis B Vaccine Schedule of Administration

The Hepatitis B vaccine as a three-dose series on a 0,1 and 6- month schedule.

- 1<sup>st</sup> Shot- The day of vaccination
- 2<sup>nd</sup> Shot- At least one month (or 28 days) after the 1<sup>st</sup> shot
- 3<sup>rd</sup> Shot- 6 Months after first shot

Rule to remember the minimum time in between shots in the series:

- Dose 2 should be separated by Dose 1 by at least one month (4 weeks or 28 days)
- Dose 3 should be separated by Dose 2 by at least two months (8 weeks) and from dose 1 by at least four months (16 weeks)

What happen if vaccine records are not there and no idea if a person ever got shot 1 and 2. There is no concern with repeating the HBV vaccine series, one has to start the series from shot 1. A hepatitis B vaccine "non-responder" refers to a person who does not develop protective surface antibodies after completing full series of hepatitis B vaccine and for whom an acute or chronic hepatitis B infection has been ruled out.

Although the majority of persons vaccinated against hepatitis B successfully respond to vaccination, an estimated 5-15% of persons may not respond. It is also possible that a person who does not respond to the vaccine may already be infected with hepatitis B. Therefore, testing for the presence of the hepatitis B virus (hepatitis B surface antigen or HBsAg) is recommended before diagnosing a person as a "vaccine non-responder." OLLEGE & HOSPITAL OFF. OMR NEAR - NAVALUR

THALAMBUR, CHENNAI-600 130.

Vaccination and antibody status of exposed person	HBsAg seropositive	Treatment when source is HBsAg negative	Treatment when source is not tested or status is unknown
Unvaccinated	HBIG* × 1 and initiate HB vaccine series	Initiate HB vaccine series	Initiate HB
Previously vaccinated Known responder†	No treatment	No treatment	
Known nonresponder	HBIG* × 2 or HBIG* × 1 and initiate revaccination	No treatment	If known high-risk source, treat as if source were HBsAg positive
Antibody response unknown	Test exposed person for anti-HBs: (1) if adequate,† no treatment; (2) if inadequate,† HBIG × 1 and vaccine booster	No treatment	Test exposed person for anti-HBs: (1) if adequate,† no treatment; (2) if inadequate,† initiate revaccination

HBsAg, Hepatitis & surface antigen; HB/G, hepatitis & Immune globulin; HB, hepatitis vaccine; ant/HBs, antibody to hepatitis & surface antigen. \*Dose 0.06 mg/kg IM.

+Responder is defined as a person with adequate serum levels of anti-HBs (>10 miL/mi); inadequate vaccination defined as serum anti-HBs <10 miL/mil.

### POST-EXPOSURE PROPHYLAXIS

Exposure to blood, tissue, or other body fluids like semen, vaginal secretions, cerebrospinal, pleural, peritoneal, pericardial, synovial, and amniotic fluids have a potential risk of transmission of blood borne pathogens to healthcare workers and therefore post-exposure prophylaxis should be considered If there is:

- A percutaneous injury (for example, a needle sticks or cut with a sharp object).
- Contact with mucous membrane or non-intact skin (for example,

skin chapped orabraded or dermatitis).

 Prolonged contact with intact skin or contact that involves extensive areas of skin.

A. Holundon

### STEPS TO BE TAKEN FOLLOWING AN EXPOSURE

Allow site to bleed

- 1. Cuts to be washed with plenty of soap and running water
- 2. Splashes into nose, mouth, skin to be flushed with water
- Mucous membrane like eyes/mouth to be irrigated with clean water or saline for 5minutes
- 4. Pricked finger should not be put into mouth
- 5. Do not squeeze blood from wound, this causes trauma and inflammation increases the risk of transmission
- Do not use bleach, alcohol, betadine or iodine, which may be caustic and causetrauma
- 7. Report immediately to the supervisor an incident reporting form is

available which is filled out and documented for follow-up

### Testing of source

Testing of the source for HIV, HBsAg and HCV should be done as early as possible after

counseling (rapid testing if available) if infective status is not known already.

Post Exposure Prophylaxis (PEP) For HIV

PEP is recommended for the following conditions

- 1. When the exposure source is HIV Reactive
- 2. When source patient is at high risk of HIV
- 3. When the status of source patient is unknown
- 4. Exposure of per-cutaneous, mucous membrane, non-intact skin by

infectioussource material

Mundon

The pharmacological regimen to be followed for post exposure prophylaxis is --

- Basic regimen: zidovudine (300 mg) +lamivudine (150mg), 12 hourly x 4 weeks
- Expanded regimen: basic regimen + nelfinavir 750 mg 8 hourly x 4 weeks
- PEP to be stopped before 8 weeks in case patient is found HIV negative

## Infection control of Communicable Disease among health care workers:

The objectives usually include the following:

(a) educating personnel about the principles of infection control and stressing

individual responsibility for infection control

(b) monitoring and investigating potentially harmful infectious exposures and

outbreaksamong personnel

- (c) providing care to personnel for work-related illnesses or exposures
- (d) identifying work-related infection risks and instituting appropriate preventive measures
- (e) containing costs by preventing infectious diseases that result in

absenteeism and disability.

Hundon

Disease/problem	Work restriction	Duration
Conjunctivitis	Restrict from patient	Until discharge
	contact and contact	ceases
	with the patient's	
	environment	
Diarrheal diseases	Restrict from patient	Until symptoms
Acute stage (diarrhea with other	contact, contact with	resolve
symptoms)	the patient's	
	environment, or food	
	handling	
Convalescent stage, Salmonella spp.	Restrict from care of	Until symptoms
	high-risk patients	resolve consult
		regarding need for
		negative stool culture
Enteroviral infections	Restrict from care of	Until symptoms
	infants, neonates, and	resolve

Hundon

PRINCIPAL SRI VENKATESWARA DENTAL COLLEGE & HOSPITAL OFF. OMR NEAR - NAVALUR THALAMBUR, CHENNAI-600 130.

	immunocompromised	
	minunocompromised	
	patients and their	
	environments	
Hepatitis A	Restrict from patient	Until 7 days after
	contact, contact with	onset of jaundice
	patient's	
	environment, and	
	food handling	
Hepatitis B	No restriction unless	
Personnel with acute or chronic	epidemiologically	
hepatitis B surface antigemia who do	linked to	
not perform exposure prone	transmission of	
procedures	infection	
Personnel with acute or chronic	Do not perform	Until hepatitis B e
hepatitis B e antigenemia who	exposure-prone	antigen is negative
perform exposure-prone procedures	invasive procedures	
	until expert opinion	
Herpes simplex		
Genital	No restriction	
Hands (herpetic whitlow)		
	Restrict from patient	Until lesions heal

A. Mundon

	1	
	contact and contact	
	with the patient's	
	environment	
Oro-facial		
	Evaluate for need to	
	restrict from care of	
	high-risk patients	
Human immunodeficiency virus	Do not perform	
	exposure-prone	
	invasive procedures	
	until expert review	
	been sought.	
Measles	Exclude from duty	Until 7 days after the
	Exclude from duty	
Active		rash appears
		From 12th day after
Post-exposure	Exclude from duty	1st exposure through
		26th day after last
		exposure or until 9
		days after onset of
		parotitis
		r

A. Hundon

Pediculosis	Restrict from patient	Until treated and
	contact	observed to be free of
		adult and immature
		lice
Pertussis		From beginning of
Active	Exclude from duty	catarrhal stage IB
		through 3rd wk after
		onset of paroxysms or
		until 5 days after start
		of effective
		antimicrobial therapy
Postexposure asymptomatic	No restriction,	
Post-exposure-symptomatic		
personnel		Until 5 days after start
	Exclude from duty	of effective antibiotic
		therapy
Rubella	Exclude from duty	Until 5 days after rash
Active		appears
Post-exposure		From 7th day after 1st
		exposure through 21st
		day after last
		exposure

A. Moluton 1

Scabies Staphylococcus au	ireus	Restrict from patient	Until cleared by
infection		contact	medical evaluation
Active, draining skin lesions			Until lesions have
		Restrict from contact	resolved
		with patients	
Carrier state		No restriction, unless	
		personnel are	
		epidemiologically	
		linked to	
		transmission of the	
		organism	
Streptococcal infection		Restrict from patient	Until 24 hours after
- group A		care contact with	adequate treatment
		patient's or food	started
		handling	
Tuberculosis		Exclude from duty	Until proved
Active disease			noninfectious
Varicella		Exclude from duty	Until all lesions dry
Active			and crust
			n Ord le surtra

A. Hotundon

Post-exposure		From 10th day after
	Exclude from duty	1st exposure through
		21st day
Zoster	Cover lesions; restrict	Until all lesions dry
Localized, in healthy	from care of high-	and crust
	risk	
Generalized or localized in immune-	Restrict from patient	Until all lesions dry
suppressed person	contact	and crust
Viral respiratory infections	Consider excluding	Until acute symptoms
	from the care of high	resolve
	risk acute febrile	
	patients or contact	
	with their	
	environment during	
	community outbreak	
	of RSV and influenza	

g. Holubon